Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Inclusion Criteria: * Diagnosis of 1 of the following hematologic malignancies: * Hodgkin's lymphoma * Non-Hodgkin's lymphoma (NHL) * Multiple myeloma * Patients in the phase II portion of the study are enrolled in 1 of the following strata according to diagnosis\* * Stratum 1: Indolent B-cell NHL (non-Hodgkin's lymphoma), follicle center B-cell NHL (grade 1, 2, or 3), marginal zone lymphoma, Waldenstrom's macroglobulinemia, or small lymphocytic lymphoma (without blood lymphocytosis at any point in the disease process) * Must have progressive lymphadenopathy, worsening cytopenias, or progressive symptoms attributed to lymphoma * Must require therapy, as determined by progressive anemia, thrombocytopenia, symptoms (e.g., fever, night sweats, weight loss, or fatigue), or progressive lymphadenopathy that causes discomfort * Received ≥ 2 prior therapies, including rituximab * Stratum 1a: Hairy cell leukemia * Must require therapy, as determined by progressive cytopenias or symptoms (fever, night sweats, weight loss, or fatigue) * Must have received ≥ 2 therapies * Stratum 2: Mantle cell lymphoma, as determined by the presence of cyclin D1 staining OR t(11;14) * Stratum 3: Intermediate grade B-cell NHL, including diffuse large B-cell NHL and T-cell rich B-cell NHL * Diffuse large B-cell NHL arising from an indolent NHL (i.e., transformed lymphoma) allowed * Ineligible for potentially curative autologous stem cell transplantation * …